Ocwaningweni olwanyatheliswa kumagazini kaNovemba we-Journal of Personalized Medicine, abacwaningi bahlola ukuthi kwenzekani lapho ama-opioid avamile afana ne-hydrocodone, oxycodone, codeine, ne-tramadol, edinga i-enzyme ethile ukuze kusebenze ukukhululeka kobuhlungu, ithathwa neminye imithi edinga. i-enzyme efanayo. Abantu abaphuze okungenani eyodwa yalawa ma-opioid kanye nesinye isidakamizwa okungenani esisodwa esiqhudelana naleyo enzyme babenezindleko zokwelashwa eziphakeme ezimaphakathi zaminyaka yonke kanye nesilinganiso esikhulu sokudla kwansuku zonke kwe-opioid kunabantu abaphuze okungenani eyodwa yalawa ma-opioid kodwa bengenazo izidakamizwa ezisebenzisanayo. Ukwengeza, abacwaningi bathola ukuthi abantu abaphuze okungenani eyodwa yalawa ma-opioid kanye nesidakamizwa okungenani esisodwa esisebenzisanayo ngokuvamile babesengozini enkulu yezinye izehlakalo zezidakamizwa ezimbi, ngokusekelwe ku-MedWise Science ye-TRHC, ecubungula lonke uhlu lwemithi yesiguli lapho kuhlolwa okuhlobene nezidakamizwa. izinkinga.
"NgeSayensi ye-MedWise, singakwazi ukubona ukuthi ubani onengozi enkulu yemiphumela emibi ngenxa yokusebenzisana kwezidakamizwa," kusho uSihlalo we-TRHC kanye no-CEO uCalvin H. Knowlton, PhD. "Ukushintsha izinqubo zamanje zokunquma ukuvimbela ukusebenzisana kwezidakamizwa kungathuthukisa ukuphepha kwemithi, okungase kuthuthukise ukusebenza kahle kwama-opioid ezigulini ezithile kuyilapho kunciphisa imiphumela emibi yesiguli kanye nezindleko ezihambisana nazo."
Ucwaningo oluhlukile ku-Journal of Palliative Medicine lusebenzise i-MedWise Science kanye namathuluzi ayo okusekela izinqumo zomtholampilo ukuze kuhlolwe idatha yofuzo ehlobene ne-opioid metabolism. Ucwaningo lubonisa ukuthi osokhemisi abasebenzisa idatha ye-pharmacogenomic bangasiza odokotela bathuthukise ukuphepha kwemithi. Ngokocwaningo, ama-85% odokotela babonise ukuthi amathuluzi okusekela izinqumo athuthukisa izinga lokunakekelwa kwesiguli ezigulini ezithatha ama-opioid.
"Ukuhlaziywa kofuzo kuletha ukwenziwa komuntu siqu kanye nokunemba enkabeni yokuphepha kwemithi," kusho u-Jacques Turgeon, i-BParm, i-PhD, i-TRHC Chief Scientific Officer kanye ne-CEO ye-Precision Pharmacotherapy Research and Development Institute. "Ukusekelwa kwezinqumo zomtholampilo nge-MedWise Science kusiza odokotela ukuba bahlukanise idatha yofuzo futhi babahlomise ngezincomo ezisebenzayo ukuze bagweme izinkinga zemithi."
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- People who took at least one of these opioids and at least one other drug that competes for that enzyme had higher average yearly medical expenses and a greater average daily opioid intake than people who took at least one of these opioids but no interacting drugs.
- Additionally, researchers found that individuals who took at least one of these opioids and at least one interacting drug generally had a greater risk of other adverse drug events, based on TRHC’s MedWise Science, which considers a patient’s entire medication list when assessing for drug-related problems.
- In a study published in the November issue of the Journal of Personalized Medicine, researchers examined what happens when common opioids such as hydrocodone, oxycodone, codeine, and tramadol, which need a particular enzyme to activate pain relief, are taken with other medications that require the same enzyme.
